- Publications
- Influence
Share This Author
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
- A. Cheng, Yoon-Koo Kang, Z. Guan
- Medicine, BiologyThe Lancet. Oncology
- 2009
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase…
- Caicun Zhou, Yi-Long Wu, C. You
- Medicine, BiologyThe Lancet. Oncology
- 1 August 2011
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase…
- Yi-Long Wu, Caicun Zhou, S. Geater
- Medicine, BiologyThe Lancet. Oncology
- 1 February 2014
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3…
- T. Mok, Yi-Long Wu, A. Zippelius
- MedicineThe Lancet
- 4 May 2019
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
- J. Yang, Yi-Long Wu, L. Sequist
- Medicine, BiologyThe Lancet. Oncology
- 1 February 2015
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- L. Paz-Ares, M. Dvorkin, Michael Williamson
- MedicineThe Lancet
- 23 November 2019
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
- Yuankai Shi, Li Zhang, Yan Sun
- Medicine, BiologyThe Lancet. Oncology
- 1 September 2013
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent…
- Caicun Zhou, Yi-Long Wu, A. Yin
- Medicine, ChemistryJournal of clinical oncology : official journal…
- 26 May 2015
TLDR
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
- F. Ma, Q. Ouyang, Bing-he Xu
- Medicine, BiologyJournal of clinical oncology : official journal…
- 20 August 2019
TLDR
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised…
- Jin-Ji Yang, Caicun Zhou, Yi-Long Wu
- MedicineThe Lancet. Respiratory medicine
- 1 September 2017
...
...